Source: Virtual Congress 2021 – Diagnosis and management of COVID-19



Rating:

Share or cite this content

Citations should be made in the following way:
R. Adams (San Diego, United States of America), G. Walker (San Diego, United States of America), L. Guy (San Diego, United States of America), L. Sitts (San Diego, United States of America), N. Kinnersley (Harpenden, United Kingdom), L. Carey (San Diego, United States of America), L. Nangle (San Diego, United States of America), S. Shukla (San Diego, United States of America). Late Breaking Abstract - Treatment with ATYR1923 reduces biomarkers in COVID-19 pneumonia. 452

Member's Comments

No comment yet.

Related content which might interest you: Late Breaking Abstract - Acute multi-organ symptoms predict long COVID Source: Virtual Congress 2021 – Diagnosis and management of COVID-19 Year: 2021 Late Breaking Abstract - Frequency and characteristics of TB relapses Source: International Congress 2017 – Late-breaking studies in pulmonary diseases Year: 2017 Late Breaking Abstract - Management of COVID-19 pneumonia in an enhanced respiratory step down unit: a novel approach. Source: Virtual Congress 2021 – Challenges of COVID-19 management at short and long-term Year: 2021 Late Breaking Abstract - Detection of clinical instability by eNose in COPD patients Source: International Congress 2018 – How far are we in terms of predicting mortality and exacerbations in COPD? Year: 2018 Late Breaking Abstract - Determinants of disease control in patients with severe COPD. The CLAVE Study Source: International Congress 2019 – Clinical approach to asthma management Year: 2019 Late Breaking Abstract - Recurrent Neural Networks and environmental data for COPD exacerbation prediction Source: Virtual Congress 2020 – Personalised treatment of obstructive diseases Year: 2020 Late Breaking Abstract - Validation of a clinical score predictive of SARS-CoV-2 infection in pneumonia inpatients Source: Virtual Congress 2020 – COVID-19 clinical studies Year: 2020 Late Breaking Abstract - Implications of new PH definition for CTEPD Source: Virtual Congress 2021 – Therapy of pulmonary hypertension Year: 2021 Late Breaking Abstract - Systemic ferritin is an early disease biomarker for silicosis patients Source: Virtual Congress 2021 – Prognostic markers of disease progression in non-idiopathic pulmonary fibrosis interstitial lung diseases Year: 2021 Late Breaking Abstract - MicroRNA profiling informs on the pulmonary sequelae of COVID-19-induced ARDS Source: Virtual Congress 2021 – Late breaking basic and translational science of SARS-Cov2 and COVID-19 Year: 2021 Late Breaking Abstract - Early response to benralizumab in Canadians with severe eosinophilic asthma Source: Virtual Congress 2021 – Asthma clinical trials and real-life studies Year: 2021 Late Breaking Abstract - Identification of patients with COPD who benefit from benralizumab Source: International Congress 2019 – ALERT: Abstracts Leading to Evolution in Respiratory Medicine Trials: COPD and cough Year: 2019 Late Breaking Abstract - Lung function before and after COVID-19 infection in young adults Source: Virtual Congress 2021 – Respiratory function after COVID-19 and mechanical ventilation Year: 2021 Late Breaking Abstract - Mepolizumab reduces exacerbations in eosinophilic COPD Source: International Congress 2017 – Late-breaking studies in asthma and COPD Year: 2017 Late Breaking Abstract - Lung function tests in patients with previous SARS-COV2 pneumonia: a useful follow-up tool Source: Virtual Congress 2021 – Exacerbations of chronic respiratory diseases, including SARS-CoV-2 Year: 2021 Late Breaking Abstract - Capnography for ultimately simple diagnostics of COPD Source: International Congress 2017 – Innovation in COPD: techniques and facts Year: 2017 Late Breaking Abstract - Variable costs of sepsis in a Greek ICU Source: Virtual Congress 2021 – Difficult decisions on expected outcomes: availability of hospital resources and improvement of treatment adherence Year: 2021 Late Breaking Abstract - Relationship between clinical features and mortality in a cohort of COPD patients. Source: Virtual Congress 2021 – Prediction of exacerbations in patients with COPD Year: 2021 Late Breaking Abstract - Role of PD-1/PD-L1 pathway in Pneumocystis pneumonia Source: International Congress 2019 – Severe pneumonia: epidemiology, mechanisms and treatment Year: 2019 Late Breaking Abstract - Rituximab limits the progression of fibrosing mediastinitis Source: International Congress 2019 – Rare and ultra-rare diseases and the lungs: updates and new perspectives Year: 2019